title: Tacrolimus and myocardial hypertrophy.
abstract: Tacrolimus has been used as an immunosuppressive agent in the transplantation of all solid organs. Tacrolimus-induced hypertrophic cardiomyopathy has been reported to be an unusual but serious complication. To elucidate the effects of tacrolimus on myocardial hypertrophy, we studied the relationship between the blood levels of tacrolimus and cardiac wall thickening. Our findings demonstrated that tacrolimus-induced myocardial hypertrophy correlated with tacrolimus blood levels, and that myocardial hypertrophy induced by tacrolimus was reversible. However, no patients developed clinically significant symptoms related to myocardial hypertrophy.
authors.affiliation: Department of Pediatrics, Kyoto University Faculty of Medicine, Kurashiki Central Hospital, Okayama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Nakata
authors.forename: M
authors.initials: M
authors.lastname: Yoshibayashi
authors.forename: T
authors.initials: T
authors.lastname: Yonemura
authors.forename: S
authors.initials: S
authors.lastname: Uemoto
authors.forename: Y
authors.initials: Y
authors.lastname: Inomata
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Furusho
mesh_terms: D000293:Adolescent; D000328:Adult; D006332:Cardiomegaly / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects*; D016559:Tacrolimus / Q000009:adverse effects* / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus